Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Jun;65(6):787–793. doi: 10.1038/bjc.1992.169

Cisplatin and its analogues in the treatment of advanced breast cancer: a review.

I E Smith 1, D C Talbot 1
PMCID: PMC1977765  PMID: 1616849

Full text

PDF
787

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bajorin D., Bosl G. J., Fein R. Phase I trial of escalating doses of cisplatin in hypertonic saline. J Clin Oncol. 1987 Oct;5(10):1589–1593. doi: 10.1200/JCO.1987.5.10.1589. [DOI] [PubMed] [Google Scholar]
  2. Bitran J. D., Kozloff M. F., Desser R. K. Platinol (CDDP) and continuous intravenous infusion 5-fluorouracil in refractory stage IV breast cancer: a phase II study. Cancer Invest. 1990;8(3-4):335–338. doi: 10.3109/07357909009012050. [DOI] [PubMed] [Google Scholar]
  3. Booth B. W., Weiss R. B., Korzun A. H., Wood W. C., Carey R. W., Panasci L. C. Phase II trial of carboplatin in advanced breast carcinoma: a Cancer and Leukemia Group B Study. Cancer Treat Rep. 1985 Jul-Aug;69(7-8):919–920. [PubMed] [Google Scholar]
  4. Calvert A. H., Harland S. J., Newell D. R., Siddik Z. H., Jones A. C., McElwain T. J., Raju S., Wiltshaw E., Smith I. E., Baker J. M. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982;9(3):140–147. doi: 10.1007/BF00257742. [DOI] [PubMed] [Google Scholar]
  5. Calvert A. H., Newell D. R., Gumbrell L. A., O'Reilly S., Burnell M., Boxall F. E., Siddik Z. H., Judson I. R., Gore M. E., Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748–1756. doi: 10.1200/JCO.1989.7.11.1748. [DOI] [PubMed] [Google Scholar]
  6. Casper E. S., Smart T. C., Hakes T. B., Ochoa M., Jr, Kaufman R. J. Clinical trial of iproplatin (cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV, CHIP) in patients with advanced breast cancer. Invest New Drugs. 1988 Jun;6(2):87–91. doi: 10.1007/BF00195365. [DOI] [PubMed] [Google Scholar]
  7. Cocconi G., Bisagni G., Bacchi M., Boni C., Bartolucci R., Ceci G., Colozza M. A., De Lisi V., Lottici R., Mosconi A. M. Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol. 1991 Apr;9(4):664–669. doi: 10.1200/JCO.1991.9.4.664. [DOI] [PubMed] [Google Scholar]
  8. Cocconi G., Tonato M., Di Costanzo F., Bisagni G., Belsanti V., Buzzi F., Ceci G. Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Eur J Cancer Clin Oncol. 1986 Jul;22(7):761–764. doi: 10.1016/0277-5379(86)90360-3. [DOI] [PubMed] [Google Scholar]
  9. Colozza M., Gori S., Mosconi A. M., Belsanti V., Basurto C., Rossetti R., Di Costanzo F., Buzzi F., Bacchi M., Davis S. Chemotherapy with cis-platin, doxorubicin, and cyclophosphamide (CAP) in patients with metastatic breast cancer. Am J Clin Oncol. 1989 Apr;12(2):137–141. doi: 10.1097/00000421-198904000-00010. [DOI] [PubMed] [Google Scholar]
  10. Cox E. B., Burton G. V., Olsen G. A., Vugrin D. Cisplatin and etoposide: an effective treatment for refractory breast carcinoma. Am J Clin Oncol. 1989 Feb;12(1):53–56. doi: 10.1097/00000421-198902000-00013. [DOI] [PubMed] [Google Scholar]
  11. Creagan E. T., Green S. J., Ahmann D. L., Ingle J. N., Edmonson J. H., Marschke R. F., Jr A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer. J Clin Oncol. 1984 Nov;2(11):1260–1265. doi: 10.1200/JCO.1984.2.11.1260. [DOI] [PubMed] [Google Scholar]
  12. Eder J. P., Elias A., Shea T. C., Schryber S. M., Teicher B. A., Hunt M., Burke J., Siegel R., Schnipper L. E., Frei E., 3rd A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol. 1990 Jul;8(7):1239–1245. doi: 10.1200/JCO.1990.8.7.1239. [DOI] [PubMed] [Google Scholar]
  13. Forastiere A. A., Hakes T. B., Wittes J. T., Wittes R. E. Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules. Am J Clin Oncol. 1982 Jun;5(3):243–247. doi: 10.1097/00000421-198206000-00001. [DOI] [PubMed] [Google Scholar]
  14. Fornasiero A., Daniele O., Aversa S. M., Ghiotto C., Morandi P., Fiorentino M. V. A 5-day regimen of cyclophosphamide, adriamycin, platinum (CAP) in refractory breast cancer. Chemioterapia. 1987 Aug;6(4):310–312. [PubMed] [Google Scholar]
  15. Gore M. E., Calvert A. H., Smith L. E. High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study. Eur J Cancer Clin Oncol. 1987 Sep;23(9):1391–1397. doi: 10.1016/0277-5379(87)90125-8. [DOI] [PubMed] [Google Scholar]
  16. Hortobagyi G. N., Frye D., Holmes F. A., Hug V., Fraschini G., Buzdar A. U. Phase II study of iproplatin in metastatic breast carcinoma. Cancer Treat Rep. 1987 Dec;71(12):1193–1196. [PubMed] [Google Scholar]
  17. Kolarić K., Roth A. Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1983;11(2):108–112. doi: 10.1007/BF00254257. [DOI] [PubMed] [Google Scholar]
  18. Kolarić K., Roth A., Vukas D., Cervek J. CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study. Cancer Chemother Pharmacol. 1984;13(2):142–144. doi: 10.1007/BF00257133. [DOI] [PubMed] [Google Scholar]
  19. Kolarić K., Tomek R. cis-platinum-based alternating non-cross-resistant chemotherapy as a first-line treatment in metastatic breast cancer. A phase II study. Tumori. 1990 Oct 31;76(5):472–475. doi: 10.1177/030089169007600511. [DOI] [PubMed] [Google Scholar]
  20. Kolarić K., Vukas D., Potrebica V. Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study. Tumori. 1989 Apr 30;75(2):132–136. doi: 10.1177/030089168907500210. [DOI] [PubMed] [Google Scholar]
  21. Krook J. E., Loprinzi C. L., Schaid D. J., Kardinal C. G., Mailliard J. A., Pfeifle D. M., Ellison N. M., Reuter N. F., Nelimark R. A. Evaluation of the continuous infusion of etoposide plus cisplatin in metastatic breast cancer. A collaborative North Central Cancer Treatment Group/Mayo Clinic phase II study. Cancer. 1990 Feb 1;65(3):418–421. doi: 10.1002/1097-0142(19900201)65:3<418::aid-cncr2820650307>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  22. Martin M., Diaz-Rubio E., Casado A., López Vega J. M. Phase II study of carboplatin in advanced breast cancer: preliminary results. Semin Oncol. 1991 Feb;18(1 Suppl 2):23–27. [PubMed] [Google Scholar]
  23. Martino S., Samal B. A., Singhakowinta A., Yoshida S., Mackenzie M., Jain J., Vaitkevicius V. K. A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer. Two dose schedules. J Cancer Res Clin Oncol. 1984;108(3):354–356. doi: 10.1007/BF00390472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mechl Z., Sopková B. CAP (cyclophosphamide, adriamycin, cisplatinum) in the treatment of advanced breast cancer. Neoplasma. 1984;31(4):431–435. [PubMed] [Google Scholar]
  25. Meisner D. J., Ginsberg S., Ditch A., Louie A., Newman N., Comis R., Poiesz B. A phase II trial of iproplatin (CHIP) in previously treated advanced breast cancer. Am J Clin Oncol. 1989 Apr;12(2):129–131. doi: 10.1097/00000421-198904000-00008. [DOI] [PubMed] [Google Scholar]
  26. Ostrow S., Egorin M., Aisner J., Bachur N., Wiernik P. H. High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. Cancer Clin Trials. 1980 Spring;3(1):23–27. [PubMed] [Google Scholar]
  27. Paridaens R., Clarysse A., Rozencweig M., Rotmensz N., Heuson J. C. Cisplatin plus vindesine in advanced breast cancer: a phase II trial of the EORTC Breast Cancer Cooperative Group. Eur J Cancer Clin Oncol. 1985 May;21(5):595–599. doi: 10.1016/0277-5379(85)90087-2. [DOI] [PubMed] [Google Scholar]
  28. Peters W. P., Shpall E. J., Jones R. B., Olsen G. A., Bast R. C., Gockerman J. P., Moore J. O. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988 Sep;6(9):1368–1376. doi: 10.1200/JCO.1988.6.9.1368. [DOI] [PubMed] [Google Scholar]
  29. Sessa C., Vermorken J., Renard J., Kaye S., Smith D., ten Bokkel Huinink W., Cavalli F., Pinedo H. Phase II study of iproplatin in advanced ovarian carcinoma. J Clin Oncol. 1988 Jan;6(1):98–105. doi: 10.1200/JCO.1988.6.1.98. [DOI] [PubMed] [Google Scholar]
  30. Sledge G. W., Jr, Loehrer P. J., Sr, Roth B. J., Einhorn L. H. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol. 1988 Dec;6(12):1811–1814. doi: 10.1200/JCO.1988.6.12.1811. [DOI] [PubMed] [Google Scholar]
  31. Sledge G. W., Jr, Roth B. J. Cisplatin in the management of breast cancer. Semin Oncol. 1989 Aug;16(4 Suppl 6):110–115. [PubMed] [Google Scholar]
  32. Smith I. E., Harland S. J., Robinson B. A., Evans B. D., Goodhart L. C., Calvert A. H., Yarnold J., Glees J. P., Baker J., Ford H. T. Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep. 1985 Jan;69(1):43–46. [PubMed] [Google Scholar]
  33. Smith I. E., Perren T. J., Ashley S. A., Woodiwiss J., Forgeson G. V., Yarnold J. R., Ford H. T. Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer. J Clin Oncol. 1990 May;8(5):899–905. doi: 10.1200/JCO.1990.8.5.899. [DOI] [PubMed] [Google Scholar]
  34. Verusio C., Bajetta E., Ferrari L., Bartoli C., Valagussa P., Bonadonna G. Cyclophosphamide, adriamycin, and cis-platinum (CAP) in metastatic and locally advanced breast cancer. Am J Clin Oncol. 1988 Aug;11(4):435–439. doi: 10.1097/00000421-198808000-00004. [DOI] [PubMed] [Google Scholar]
  35. Wiltshaw E. Ovarian trials at the Royal Marsden. Cancer Treat Rev. 1985 Sep;12 (Suppl A):67–71. doi: 10.1016/0305-7372(85)90020-9. [DOI] [PubMed] [Google Scholar]
  36. Yap H. Y., Salem P., Hortobagyi G. N., Bodey G. P., Sr, Buzdar A. U., Tashima C. K., Blumenschein G. R. Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. Cancer Treat Rep. 1978 Mar;62(3):405–408. [PubMed] [Google Scholar]
  37. Zaniboni A., Marpicati P., Simoncini E., Gorni F., Ferrari V., Raffaglio E., Garattini M. P., Marini G. Cyclophosphamide, epirubicin and cisplatin (CEP) in advanced breast cancer: preliminary results. Anticancer Res. 1987 Jul-Aug;7(4B):813–815. [PubMed] [Google Scholar]
  38. van Glabbeke M., Renard J., Pinedo H. M., Cavalli F., Vermorken J., Sessa C., Abele R., Clavel M., Monfardini S. Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG). Eur J Cancer Clin Oncol. 1988 Feb;24(2):255–262. doi: 10.1016/0277-5379(88)90262-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES